KRSA

Korsana Biosciences Inc

31.65

Nov 13 • 3:59 PM ET +0.37 (1.18%)

31.65

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: DNLI AVXL PRTA ANVS ACIU ALEC ABOS CGTX BIIB INMB

| Held by: VXF ONEQ DFSU DXUV DFAC DCOR

Scroll to Statements

Index	-
Market Cap	1.44B
Enterprise Value	1.01B
Income	-52.16M
Sales	1.02M
Book/sh	8.60
Cash/sh	10.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	Mar 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	1413.12
P/B	3.68
P/C	3.16
P/FCF	-
EV/EBITDA	-
EV/Sales	991.56
Quick Ratio	10.42
Current Ratio	10.42
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-13.07
EPS next Y	-
EPS next Q	-0.88
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	62.05% 53.53%
Sales past 3/5Y	91.14% -2.01%
EPS Y/Y TTM	-146.07%
Sales Y/Y TTM	-64.10%
EPS Q/Q	-62.02%
Sales Q/Q	-100.00%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	-276.62% -

Insider Own	1.27%
Insider Trans	0.00%
Inst Own	27.36%
Inst Trans	37.67%
ROA	-22.08%
ROE	-24.48%
ROIC	-12.49%
Gross Margin	-
Oper. Margin	-5277.27%
Profit Margin	-5088.39%
SMA20	1.27%
SMA50	0.19%
SMA200	37.49%
Trades

Shs Outstand	45.54M
Shs Float	44.96M
Short Float	0.37%
Short Ratio	1.77
Short Interest	0.17M
52W High	59.36 -46.68%
52W Low	7.19 340.43%
Volatility	6.27% 7.03%
ATR (14)	2.28
RSI (14)	51.19
Beta	1.84
Rel Volume	2.39
Avg Volume	94.35K
Volume	225,519

Perf Week	1.93%
Perf Month	-5.94%
Perf Quarter	12.19%
Perf Half Y	44.92%
Perf YTD	256.02%
Perf Year	213.99%
Perf 3Y	105.52%
Perf 5Y	-91.60%
Perf 10Y	-
Recom	1.00
Target Price	51.20
Prev Close	31.28
Price	31.65
Change %	1.18%

Consensus

Strong Buy

Avg. Price Target

$51.20

Implied Upside

+61.8%

Analysts9incl. previous ratings

Rating Distribution8 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 13, 2026	Initiated	WWells Fargo	Overweight	$44	+39.0%
Oct 05, 2026	Initiated	WWedbush	Outperform	$44	+39.0%
Sep 28, 2026	Initiated	GGuggenheim	Buy	$70	+121.2%
Sep 14, 2026	Initiated	TTD Cowen	Buy
Sep 14, 2026	Initiated	SStifel	Buy	$43	+35.9%
Sep 11, 2026	Initiated	UUBS	Buy	$55	+73.8%
Oct 20, 2021	Initiated	TTruist	Buy	$14	-55.8%
Sep 24, 2021	Initiated	CCantor Fitzgerald	Overweight	$7	-77.9%
Jun 03, 2019	Initiated	CCredit Suisse	Neutral

Nov-05-26 07:00AM	Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-26 04:05PM	Korsana Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.04%
May-04-26 02:55PM	Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-09-26 03:30PM	Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? (PR Newswire) +9.34%
Apr-01-26 10:30AM	BC-Most Active Stocks (Associated Press) +311.61%
07:05AM	Loading…
07:05AM	Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement (Business Wire)
Feb-17-26 07:00AM	Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board (GlobeNewswire)
Jan-05-26 04:01PM	Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression (GlobeNewswire) +41.30%
Nov-10-25 09:16AM	EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network (Benzinga) +10.97%
Sep-23-25 04:01PM	Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company (GlobeNewswire) +7.62%
Dec-17-24 08:08AM	Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth (GlobeNewswire) -7.08%
Aug-07-24 07:00AM	Regina Graul, Ph.D., Promoted to Chief Executive Officer (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +17.98%
May-08-24 08:52AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
03:54PM	Loading…
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39% +14.06%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire) -11.54%
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
02:31PM	Loading…
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62% -5.39%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -5.42%
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90% -5.42%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire) +8.16%
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire) +14.72%
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80% +5.78%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MICHAEL HIGGINS	Director	Oct 22 '26	Proposed Sale	32.00	1,107	35,424		Oct 22 04:06 PM
ERROL B DE SOUZA	Director	Sep 23 '26	Proposed Sale	34.99	4,903	171,556		Sep 23 04:50 PM
ERROL B DE SOUZA	Director	Sep 22 '26	Proposed Sale	34.99	100	3,499		Sep 22 04:56 PM
ERROL B DE SOUZA	Director	Sep 18 '26	Proposed Sale	34.99	2,139	74,844		Sep 18 04:49 PM
CHICKO RHONDA M.	Chief Financial Officer	Aug 14 '26	Option Exercise	2.35	25,000	58,875	25,018	Aug 18 05:27 PM
Graul Regina Margaret	See Remarks	Aug 14 '26	Option Exercise	3.30	55,849	184,302	156,152	Aug 18 05:21 PM

Korsana Biosciences, Inc. is a biopharmaceutical company, which engages in discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its portfolio includes the KRSA-028 pipeline. The company was founded in 2024 and is headquartered in Waltham, MA.

Ph.D.Dr. Jonathan Violin M.B.A.

Chief Financial OfficerDr. Mark Joseph Vignola Ph.D.

Chief Technical OfficerDr. Gan Wei Ph.D.

Chief Medical OfficerDr. Matthew Leoni M.D.

M.B.A.Mr. Kyle Breidenstine CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

KRSA

Korsana Biosciences Inc

Upgrade your Finviz experience

All the Features.
Half the Price.